Dear Ms. Larino:

Please refer to your Supplemental New Drug Application (sNDA), dated and received July 5, 2018, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Claritin (loratadine) chewable tablets, 5 mg.

This “Prior Approval” supplemental new drug application provides for five hangtag instantly redeemable coupons (IRCs).

We have completed our review of this application. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

**LABELING**

Submit final printed labeling (FPL) as soon as they are available, but no more than 30 days after they are printed. The FPL must be identical to the enclosed labeling described in the table below and must be in the “Drug Facts” format (21 CFR 201.66), where applicable.

**Table 2: Labeling Recommended for Approval**

<table>
<thead>
<tr>
<th>Labeling Item</th>
<th>Submission Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hangtag coupon for $1 off 10-count or larger</td>
<td>07/05/18</td>
</tr>
<tr>
<td>Hangtag coupon for $2 off 20-count or larger</td>
<td>07/05/18</td>
</tr>
<tr>
<td>Hangtag coupon for $3 off 20-count or larger</td>
<td>07/05/18</td>
</tr>
<tr>
<td>Hangtag coupon for $3 off 30-count only</td>
<td>07/05/18</td>
</tr>
<tr>
<td>Hangtag coupon for $4 off 30-count only</td>
<td>07/05/18</td>
</tr>
</tbody>
</table>
The FPL should be submitted electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (April 2017, Revision 4)*. For administrative purposes, designate this submission “Final Printed Labeling for approved NDA 21891/S-28.” Approval of this submission by FDA is not required before the labeling is used.

**DRUG REGISTRATION AND LISTING**

All drug establishment registration and drug listing information is to be submitted to FDA electronically, via the FDA automated system for processing structured product labeling (SPL) files (eLIST). At the time that you submit your final printed labeling (FPL), the content of labeling (Drug Facts) should be submitted in SPL format as described at [http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm](http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm). Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at [http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf](http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf). In addition, representative container or carton labeling, whichever includes Drug Facts, (where differences exist only in the quantity of contents statement) should be submitted as a JPG file.

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Sherry Stewart, Regulatory Project Manager, at 301-796-9618.

Sincerely,

*{See appended electronic signature page}*

Theresa Michele, MD
Director
Division of Nonprescription Drug Products
Office of Drug Evaluation IV
Center for Drug Evaluation and Research

**ENCLOSURES:**

Instantly Redeemable Coupons
This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

THERESA M MICHELE
01/03/2019 12:36:11 PM